Clinical

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Panelists discuss how iron deficiency anemia manifests through debilitating symptoms, including severe fatigue, weakness, shortness of breath, headaches, and difficulty concentrating, which can profoundly impact patients’ daily functioning, work performance, and overall quality of life.

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Acts of discrimination, including subtle microaggressions, during pregnancy and childbirth contribute to higher maternal mortality rates, especially among Black women, and are linked to increased postpartum blood pressure, highlighting the need for improved health care interventions and racial equity in maternity care.

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).

Doctors conducted suicide risk assessments for 42% of patients flagged by interruptive alerts, compared with only 4% with passive alerts.

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, delivering comparable outcomes to rheumatologist-led care and usual care while easing health care burdens.

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients treated for pediatric acute myeloid leukemia (AML).

A panelist discusses how digital patient engagement tools and collaboration with advocacy groups can enhance treatment adherence and care coordination while providing vital support and resources for individuals managing Lambert-Eaton myasthenic syndrome (LEMS).

Dr. Bijal Shah shares insights on anticipated updates to NCCN guidelines for Ph+ ALL, emphasizing key areas of focus to address gaps and advance patient care.

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production. Characterized by repeated episodes of colitis, it predominantly affects older, hospitalized patients with compromised immune systems, presenting significant clinical challenges through inflammatory complications and potential systemic spread.

The panelist discusses how early detection of recurrent Clostridioides difficile infections is critical in clinical practice because these infections can rapidly escalate patient morbidity and mortality. Recurrent C difficile infections are associated with significantly increased mortality rates, with studies showing that patients experiencing multiple infection episodes have a higher risk of complications, prolonged hospital stays, and increased health care costs. Early identification allows for prompt intervention, which can help prevent disease progression, reduce transmission risks, and implement targeted treatment strategies.

Compared with female patients, male patients with eosinophilic esophagitis have higher rates of complications, including esophageal obstruction, food impaction, and rupture, highlighting potential gender differences in disease severity.

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.

Panelists discuss how iron deficiency anemia significantly impacts patients’ quality of life through symptoms like chronic fatigue, shortness of breath, and cognitive dysfunction, while also creating substantial psychosocial burdens including depression, reduced work productivity, and social isolation, particularly affecting vulnerable populations who may face barriers to diagnosis and treatment.

Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.